GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DanZ who wrote (557)	5/8/1999 11:40:00 PM
From: Mad2	Read Replies (1) of 5582

Dan, do you have any published source or filing where you got the information that Gel Tech LLC owns the tradename and intellectual property on Zicam. I'm not disputing this, however everything I have seen and read (excepting your post) represents Gel Tech LLC interests to be in the marketing and distribution: From GUMM's 5/6/99 press release The joint venture will market and distribute ZICAM(TM), a new homeopathic cold remedy. ZICAM(TM) uses a nasal gel to deliver its active ingredient, Zinullose(TM), a patent-pending ionic zinc emulsification formula. Initial research has shown that ZICAM(TM) reduces the duration of the common cold from an average of 10 - 14 days to an average of 1 - 3 days. Under the terms of the operating agreement, Gum Tech will own a 60% interest and BioDelivery Technologies will own a 40% interest in Gel Tech LLC. Dan, I'm trying to understand who owns the patent for Zinullose and any other property rights. If so what are the financial and other terms. Best Regards, Mad2

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next